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Abstract
Objective To assess the cost effectiveness of adding spinal
manipulation, exercise classes, or manipulation followed by
exercise (“combined treatment”) to “best care” in general
practice for patients consulting with low back pain.
Design Stochastic cost utility analysis alongside pragmatic
randomised trial with factorial design.
Setting 181 general practices and 63 community settings for
physical treatments around 14 centres across the United
Kingdom.
Participants 1287 (96%) of 1334 trial participants.
Main outcome measures Healthcare costs, quality adjusted life
years (QALYs), and cost per QALY over 12 months.
Results Over one year, mean treatment costs relative to “best
care” were £195 ($360; €279; 95% credibility interval £85 to
£308) for manipulation, £140 (£3 to £278) for exercise, and
£125 (£21 to £228) for combined treatment. All three active
treatments increased participants’ average QALYs compared
with best care alone. Each extra QALY that combined
treatment yielded relative to best care cost £3800; in economic
terms it had an “incremental cost effectiveness ratio” of £3800.
Manipulation alone had a ratio of £8700 relative to combined
treatment. If the NHS was prepared to pay at least £10 000 for
each extra QALY (lower than previous recommendations in the
United Kingdom), manipulation alone would probably be the
best strategy. If manipulation was not available, exercise would
have an incremental cost effectiveness ratio of £8300 relative to
best care.
Conclusions Spinal manipulation is a cost effective addition to
“best care” for back pain in general practice. Manipulation
alone probably gives better value for money than manipulation
followed by exercise.
Introduction
Back pain is a major economic problem. Before the accompany-
ing clinical paper,1 little evidence existed for the effectiveness of
two commonly used treatments—exercise classes and spinal
manipulation. Until the UK BEAM trial, little evidence existed
for the cost effectiveness of those treatments.2 3
An economic evaluation in British primary care found that
physiotherapy led exercise classes were less expensive and more
effective than general practice care alone.4 In contrast, a Finnish
study found that patients randomised to exercise, different from
that investigated by the British study, had higher costs and
poorer outcomes than those randomised to the control group
and encouraged to keep active.5 A Swedish study found no
differences in costs or outcomes between physiotherapy and chi-
ropractic manipulation.6 In contrast, a UK trial comparing
private chiropractic and NHS outpatient treatment found that
reductions in time off work more than offset the net health serv-
ice cost incurred by chiropractic.7 To reduce the uncertainty sur-
rounding the cost effectiveness of these physical treatments for
back pain, we report the economic evaluation of the UK BEAM
trial.
Methods
Interventions
“Best care” in general practice (the “comparator” treatment)—We
trained practice teams in “active management” and provided The
Back Book for patients.8 9
Exercise programme—This comprised an initial assessment and
up to nine classes in community settings over 12 weeks.10
Spinal manipulation package—The UK chiropractic, osteo-
pathic, and physiotherapy professions agreed to use a package of
techniques developed by a multidisciplinary group, during eight
sessions over 12 weeks.11
Combined treatment—Participants received six weeks of
manipulation followed by six weeks of exercise. Treatments were
otherwise those given to the manipulation only or exercise only
groups.
Study design
We randomised participants between these four interventions.
We also randomised participants receiving manipulation
between private and NHS premises. Thus the study had a three
by two factorial design. As the accompanying clinical paper did
not find statistically significant differences in outcome between
manipulation in NHS and private premises, this paper analyses
the simpler two by two factorial trial.
Data collection
Participants completed questionnaires, including the EQ-5D
health status instrument,12 13 at baseline, three months, and 12
months. Over the same period they recorded use of health
care—including hospital stays, visits to secondary and primary
care, and physical therapists, both private and within the NHS—
whether related to back pain or not. Physical therapists
completed record forms, including the number of treatments
they delivered.
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Unit costs
To contribute to health policy for an expensive condition, we
conducted an economic analysis from the perspective of health
care. Participants’ follow up periods lay between August 1999
and April 2002. We therefore used unit costs in pounds sterling
at 2000-1 prices to value the resources they used (table 1).We did
not adjust or discount the costs, as we focused on effects over
only one year. We costed NHS care from national averages for
England.14 15 We costed private care by using information from a
major insurance provider.16 As the accompanying paper found
no difference in clinical outcome between manipulation in
private and NHS premises,1 our main economic analysis used
costs for the less expensive NHS premises. Nevertheless, we
explored this assumption in a sensitivity analysis.
Health outcomes
The EQ-5D measures health on five three point scales—mobility,
self care, usual activities, pain-discomfort, and anxiety-
depression—thus putting participants into one of 243 ( = 35)
health states.12 A large British sample valued these states on a
“utility” scale on which being dead scores zero and perfect health
scores one.13 We estimated how many quality adjusted life years
(QALYs) participants had experienced over their year in the UK
BEAM trial by calculating “areas under (health utility) curves.”17
For example, if they reported that their utility averaged 0.5, we
calculated that they had experienced half a QALY over the year
in UK BEAM. To avoid bias we adjusted for differences in base-
line EQ-5D scores.18
Cost utility analysis
Because the accompanying clinical paper found statistically
significant interactions between manipulation and exercise,1 it
compares four distinct treatments within the factorial design.19
Although costs show no interaction between treatments, this
paper also compares these four treatments for three reasons.
Firstly, as costs vary much more than clinical outcomes, this is
prudent. Secondly, those people responsible for allocating
resources need to choose between these four treatments. Finally,
this epitomises the Bayesian statistical approach adopted in this
paper.
So we estimated the mean costs of, and mean QALYs gained
by, each of four distinct treatments. As most trials compare just
two treatments, we adopted a more general approach. Firstly, we
ranked treatments by mean cost, starting from the least costly.
Secondly, we calculated incremental cost effectiveness ratios for
all treatments by dividing incremental costs by incremental
QALYs. Finally, we excluded from the comparison “dominated”
treatments and treatments subject to “extended dominance,”20
and we recalculated ratios if necessary. A treatment is dominated
if it generates worse health outcomes and costs more than an
alternative treatment. Extended dominance occurs when a treat-
ment is less effective and has a higher incremental cost effective-
ness ratio than an alternative treatment.20
Trial participants registered with the same general practice
formed clusters within centres, and centres formed clusters
within the trial. In these circumstances, the use of standard cost
utility methods may yield misleading results.21 Hence we used
Bayesian Markov Chain Monte Carlo methods within the statis-
tical package MLwiN to undertake bivariate multilevel analysis.22
Because evidence about the cost effectiveness of physical
treatments for back pain is weak, we started by giving each of the
four treatments “uninformative” prior probabilities. In other
words, we made no assumptions about the probabilities before
UK BEAM that one treatment was more effective or cost more
than another.
To report the uncertainty due to sampling variation, we
calculated Bayesian credibility intervals (Bayesian analogue of
95% confidence intervals) and plotted cost effectiveness accept-
ability curves.23 24 As UK BEAM compared four rather than two
treatments, we plotted multi-treatment cost effectiveness accept-
ability curves. These curves show the posterior (after UK BEAM)
probability that each strategy is better than the other three across
the range of values that decision makers may pay to achieve an
additional QALY. This assumes that these people have
maximum values that they are willing to pay for an additional
QALY. It is this “ceiling” against which they should compare esti-
mated incremental cost effectiveness ratios and read the
probability that the corresponding treatment is “best.” This deci-
sion oriented formulation selects as “best” or “cost effective” that
treatment, with an incremental cost effectiveness ratio below the
ceiling, likely to be more effective than competing treatments.
This is not necessarily the strategy with the lowest ratio, as that
may generate fewer QALYs.23 To cover scenarios in which either
exercise or manipulation is not available, we also plotted
two-treatment cost effectiveness acceptability curves to compare
best care with manipulation alone or exercise alone.
Finally, we did three sensitivity analyses to explore how
dependent the results were on participants’ estimates of total
costs and our estimates of unit costs. The first analysis examined
the influence of cost “outliers,” very large healthcare costs
reported by a few participants. We excluded those participants
whose costs exceeded £2000 ($3700; €2900) (more than eight
times the median cost) in case their chance allocation between
groups had distorted the results.
The other two sensitivity analyses assessed the influence of
the unit costs of manipulation. One did so by costing the
scenario in which the NHS buys all manipulation from the
private sector using private manipulation costs. The other did so
by costing the scenario in which the NHS buys half its manipula-
tion from the private sector, using private costs when trial
manipulation took place in private premises and NHS costs
when in NHS premises.
Table 1 Reported cost of units of healthcare resource
Healthcare resource Unit Cost per unit (£)
Spinal manipulation package15:
Initial consultation (40 minutes) Session 24.33
Treatment session (20 minutes) Session 12.17
Exercise programme:
Initial assessment (40 minutes)15 Session 25.34
Class (assuming mean of 10 participants per class)6 Session 4.35
Hospital inpatient stay:
NHS routine admission14 15 Day 181.00
NHS emergency admission14 15 Admission 282.00
Private hospital admission16 Day 395.00
Outpatient attendance:
NHS specialist15 Visit 68.00
Private specialist16 Visit 120.00
NHS physiotherapist15 Visit 24.54
Private physiotherapist16 Visit 76.00
Other NHS15 Visit 24.54
Other private16 Visit 76.00
General practice consultation:
General practitioner15 Visit 21.50
Practice nurse15 Visit 8.50
Physiotherapist15 Visit 15.00
Other healthcare professional15 Visit 15.00
Primary care
page 2 of 6 BMJ Online First bmj.com
Results
Recruitment
We recruited 1334 participants from 181 practices around 14
centres across the United Kingdom. Of these, 1287 (96.5%)
yielded enough data for inclusion in the economic analysis; 326
received best care in general practice, 297 received best care plus
exercise, 342 received best care plus manipulation, and 322
received best care plus combined treatment.
Clinical outcomes
The accompanying clinical paper reports that exercise achieved
a small functional benefit at three months but not at one year;
manipulation achieved a small to moderate benefit at three
months and a small benefit at one year; and combined treatment
achieved a moderate benefit at three months and a small benefit
at one year (all statistically significant).1 These benefits were spe-
cific to back pain, in contrast to the general health benefits deter-
mined in this paper.
Costs
Combined treatment had the highest therapy costs but the low-
est subsequent hospital costs (table 2). So it cost only £125 (95%
credibility interval £21 to £228) more than best care, whereas
exercise cost £140 (£3 to £278) more than best care, and
manipulation cost £195 (£85 to £308) more.
Health outcomes
Physical interventions improved EQ-5D scores more than did
best care (table 3). Relative to best care, manipulation generated
a mean of 0.041 (95% credibility interval 0.016 to 0.066) QALYs
per participant, combined treatment generated 0.033 ( − 0.001 to
0.067), and exercise generated 0.017 ( − 0.017 to 0.051).
Cost utility analysis
When manipulation and exercise are both available, combined
treatment generates 0.033 more QALYs than does best care at
an additional cost of £125, yielding an incremental cost effective-
ness ratio of £3800 (table 4). This achievement dominates that of
exercise alone, which costs more and achieves less over 12
months. Manipulation alone, however, can generate 0.008 more
QALYs than combined treatment for an extra £70, yielding a
ratio of £8700 relative to combined treatment. If exercise is not
available, however, manipulation generates 0.041 more QALYs
than best care, yielding an incremental cost effectiveness ratio of
£4800. If manipulation is not available, exercise generates 0.017
more QALYs than best care, yielding a ratio of £8300.
The cost effectiveness acceptability curves in the top panel of
the figure show the probability that each of the four treatments is
better than the other three when all are available. If the ceiling
was only £2000 per QALY, the top panel shows 74% probability
that best care would be the best strategy. If the ceiling was £5000
per QALY, combined treatment has a lower incremental cost
effectiveness ratio than this; the top panel of the figure shows a
46% chance that it would be best. If the ceiling was £15 000 per
QALY (lower than implied by previous recommendations by the
National Institute for Clinical Excellence25), manipulation alone
has a lower incremental cost effectiveness ratio than this; the top
Table 2 Reported mean (SD) cost (£) of health care over 12 months by treatment group
Healthcare resource
Best care in general practice
(n=326)
Best care plus exercise alone
(n=297)
Best care plus manipulation alone
(n=342)
Best care plus manipulation and
exercise (n=322)
Spinal manipulation within UK BEAM 0 0 147 (53) 115 (53)
Exercise class within UK BEAM 0 41 (22) 0 37 (22)
Hospital inpatient stay:
NHS routine admission 28 (148) 31 (197) 17 (91) 19 (114)
NHS emergency admission 11 (86) 17 (112) 20 (128) 14 (106)
Private hospital admission 6 (66) 5 (85) 5 (71) 7 (86)
Outpatient attendance:
NHS specialist 63 (186) 63 (234) 51 (150) 34 (121)
Private specialist 14 (85) 42 (470) 16 (110) 13 (110)
NHS physiotherapist 22 (103) 27 (195) 27 (165) 11 (60)
Private physical therapist* 56 (280) 44 (335) 103 (428) 49 (216)
Other NHS 20 (146) 11 (62) 14 (90) 12 (69)
Other private 23 (145) 28 (195) 23 (196) 13 (79)
General practice consultation:
General practitioner 88 (139) 63 (129) 94 (146) 73 (118)
Practice nurse 4 (18) 7 (48) 9 (44) 5 (33)
Physiotherapist 1 (4) 102 (125) 4 (28) 57 (63)
Other 11 (55) 5 (30) 11 (51) 10 (44)
Total cost 346 (602) 486 (907) 541 (768) 471 (490)
*Including spinal manipulation or exercise class outside UK BEAM.
Table 3 Utilities and QALYs over 12 months by treatment group
Best care in general
practice (n=326)
Best care plus exercise
alone (n=297)
Best care plus manipulation
alone (n=342)
Best care plus manipulation
and exercise (n=322)
Mean (SD) utility from EQ-5D* at:
Baseline 0.597 (0.233) 0.556 (0.270) 0.592 (0.247) 0.596 (0.241)
Three months 0.626 (0.249) 0.620 (0.262) 0.675 (0.261) 0.660 (0.241)
One year 0.629 (0.263) 0.618 (0.267) 0.664 (0.277) 0.679 (0.268)
Mean (SD) QALYs over 12 months* 0.618 (0.232) 0.635 (0.245) 0.659 (0.241) 0.651 (0.237)
Difference (95% credibility interval) in mean QALYs
relative to best care in general practice*
Not applicable 0.017 (−0.017 to 0.051) 0.041 (0.016 to 0.066) 0.033 (−0.001 to 0.067)
QALY=quality adjusted life year.
*Estimated by analysis of covariance with adjustment for baseline EQ-5D score and then rounded to three significant figures.
Primary care
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panel shows a 50% probability that it would be best. The cost
effectiveness acceptability curve in the middle panel of the figure
shows the probability that manipulation is better than best care
when exercise is not available; and vice versa for the curve in the
bottom panel.
Sensitivity analyses
To assess the robustness of these results to the presence of “out-
liers,” we excluded the 51 participants (9, 16, 16, and 10 from best
care, exercise alone, manipulation alone, and combined
treatment respectively) whose healthcare costs exceeded £2000.
Manipulation achieves extended dominance over both exercise
and combined treatment (table 5). It is thus the only alternative
to best care, with an incremental cost effectiveness ratio of £3000
per additional QALY. At a ceiling of £10 000 per QALY,
manipulation has a 73% chance of being best. If manipulation
alone were not available, exercise would have a ratio of £4100.
The second sensitivity analysis used private costs for manipu-
lation that took place in private premises. Combined treatment
now achieves extended dominance over exercise, with an
incremental cost effectiveness ratio of £6600 compared with best
care (table 5). Manipulation alone then has a ratio of £8700 rela-
tive to combined treatment
The third sensitivity analysis used private unit costs for all
manipulation within the trial. The findings are analogous to
those in the second scenario. Exercise is subject to extended
dominance, and combined treatment has an incremental cost
effectiveness ratio of £8600 compared with best care (table 5).
Manipulation alone then has a ratio of £10 600 relative to com-
bined treatment.
Discussion
Principal findings
This economic evaluation supports and extends the findings of
the clinical evaluation of the UK BEAM trial reported in the
accompanying paper.1 If decision makers value additional quality
adjusted life years (QALYs) at much less than £3800, “best care”
in general practice is probably the best strategy. If their valuation
lies between £3800 and £8700, spinal manipulation followed by
exercise classes (“combined treatment”) is likely to be the best
treatment. If their valuation is well above £8700, manipulation
alone is probably the best treatment.
Strengths and weaknesses of the study
Although two of our three sensitivity analyses—those that used
larger unit costs in whole or in part—changed these critical
thresholds a little, they did not alter the essentials of these
conclusions. The other sensitivity analysis, which removed 51
“outliers” from the UK BEAM dataset, was more favourable to
manipulation than was the primary analysis. Under this scenario
manipulation cost only £3000 per QALY relative to best care in
general practice.
We believe that this is the first study of physical therapy for
low back pain to show convincingly that both manipulation
alone and manipulation followed by exercise provide cost effec-
tive additions to care in general practice. Indeed, as we trained
practice teams in the best care of back pain, we may have under-
estimated the benefit of physical therapy when compared with
“usual care” in general practice. The detailed clinical outcomes
reported in the accompanying paper reinforce these findings by
showing that the improvements in health status reported here
reflect statistically significant improvements in function, pain,
disability, physical and mental aspects of quality of life, and
beliefs about back pain.1
Unanswered questions
Funding constraints prevented us from following up participants
for more than 12 months. Given that they continued to show
Table 4 Cost utility analysis by scenario and treatment group*
Treatment group
Mean cost*
(£)
Mean adjusted
QALYs*†
Incremental cost
effectiveness ratio to
nearest £100 or comment
Manipulation and exercise both available (n=1287)
Best care in general practice 346 0.618
Best care plus exercise 486 0.635 Dominated by combined
treatment, which costs less
and gains more QALYs
Best care plus manipulation
and exercise
471 0.651 £3800
Best care plus manipulation 541 0.659 £8700 relative to
manipulation and exercise
Exercise not available (n=623)
Best care in general practice 346 0.622
Best care plus manipulation 541 0.663 £4800 relative to best care
Manipulation not available (n=668)
Best care in general practice 346 0.610
Best care plus exercise 486 0.627 £8300 relative to best care
QALY=quality adjusted life year.
*Markov Chain Monte Carlo estimates from bivariate multilevel model.
†Estimated by analysis of covariance with adjustment for baseline EQ-5D score and then
rounded to three significant figures.
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benefits of treatment at 12 months, the cost effectiveness of both
manipulation and combined treatment may be better than we
have reported.
Commissioning decisions should depend on local circum-
stances, notably the availability of spinal manipulation and exer-
cise physiotherapists. Although combined therapy is an attractive
option, this depends on an ample supply of both trained
manipulators prepared to work for the NHS and exercise physi-
otherapists with access to suitable premises. As back pain is a
common problem, making manipulation generally available will
require many therapists. In the United Kingdom there are 2100
registered chiropractors, 3200 registered osteopaths, and about
5000 manipulative physiotherapists (Ann Thomson, Chair of
British Association of Chartered Physiotherapists in Manipula-
tion, on behalf of the Chartered Society of Physiotherapy,
personal communication, 2003). According to the unit costs we
used in our analysis, they can achieve higher incomes in private
practice than in the NHS. In the short term it may be difficult to
make manipulative or combined treatment generally available
within the NHS.
Whereas physiotherapists can rapidly train to deliver the
exercise package, insufficient trained manipulators are available
in the United Kingdom to meet potential demand, and it will
take several years to produce additional manipulators. Indeed, if
this needs new training programmes, it may be decades before
the NHS can implement these findings. Fortunately, using
private costs for manipulation had little effect on the choice of
best treatment. Purchasing manipulation from the private sector
to provide treatment within the NHS would still represent good
value for money if decision makers were willing to pay £10 000
per additional QALY.
Meaning of the study
Adding spinal manipulation to best care in general practice is
effective and cost effective for patients with back pain in the
United Kingdom. If the NHS can afford more than £10 000 for
an extra QALY, manipulation alone probably gives better value
for money than manipulation followed by exercise. These
conclusions hold even if the NHS has to buy spinal manipulation
from the private sector.
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Amendment
This is Version 2 of the paper. In this version, the text relating
to the figure has been amended to state that the curve in the
middle panel shows the probability that manipulation is
better than best care when exercise is not available, and vice
versa for the curve in the bottom panel [these were
incorrectly given the other way round in the previous
version].
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